Premium
Effects of medroxalol on renal function and the renin‐angiotensin‐aldosterone axis
Author(s) -
Wallin J David,
Jones Phillip,
O'Neill William M,
Kuzma Ronald J,
Morgan Margoth,
Rolf Clyde
Publication year - 1984
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1984.158
Subject(s) - plasma renin activity , aldosterone , endocrinology , medicine , renal function , renin–angiotensin system , inulin , hippuric acid , chemistry , excretion , vasodilation , agonist , vascular resistance , pah clearance , blood pressure , renal blood flow , effective renal plasma flow , receptor , urine , biochemistry
Ten subjects with hypertension received medroxalol, which blocks both α‐ and β‐adrenergic receptors, has intrinsic sympathomimetic β 2 ‐agonist properties and is a direct vasodilator. Renal function tests consisting of inulin clearance and p‐amino hippuric acid (PAH) clearance, plasma renin activity (PRA) in recumbent and upright postures, and aldosterone excretion rate were performed. After intravenous medroxalol, inulin clearance and PAH clearance rose, renal vascular resistance fell, recumbent PRA was unchanged, and the rise in PRA with upright posture was blunted. After 1 mo on oral medroxalol, blood pressure was controlled while inulin clearance, PAH clearance, and renal vascular resistance were unchanged. The rise in PRA with upright posture remained blunted. Urinary aldosterone excretion was unchanged after 1 mo on medroxalol. Clinical Pharmacology and Therapeutics (1984) 36, 169–173; doi: 10.1038/clpt.1984.158